EMEA-002492-PIP01-18

Key facts

Active substance
Bempegaldesleukin
Therapeutic area
Oncology
Decision number
P/0298/2019
PIP number
EMEA-002492-PIP01-18
Pharmaceutical form(s)
Powder for concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of all conditions included in the category of malignant neoplasms (except nervous system, haematopoetic, and lymphoid tissue neoplasms)
Route(s) of administration
Intravenous use
Contact for public enquiries
Nektar Therapeutics

E-mail: studyinquiry@nektar.com
Tel. +1 8554 828676

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating